BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype

Roberta Zuntini, Laura Cortesi, Daniele Calistri, Tommaso Pippucci, Pier Luigi Martelli, Rita Casadio, Elisa Capizzi, Donatella Santini, Sara Miccoli, Veronica Medici, Rita Danesi, Isabella Marchi, Valentina Zampiga, Michelangelo Fiorentino, Simona Ferrari, Daniela Turchetti

Research output: Contribution to journalArticlepeer-review


We have investigated the clinical significance of the BRCA1 variant p.His1673del in 14 families from the Emilia-Romagna region of Italy, including 20 breast and 23 ovarian cancer cases; four families displayed site-specific ovarian cancer. The variant, absent in human variation databases, has been reported three times in BRCA1 specific databases; all probands shared the same rare haplotype at the BRCA1 locus, consistent with a common ancestor. The multifactorial likelihood method by Goldgar, used to estimate the probability of the variant being causative, gave a ratio of 2,263,474:1 in favor of causality. Moreover, in silico modeling suggested that His1673-lacking BRCA1 protein may have a decreased ability to bind BARD1 and other related proteins. All six ovarian carcinomas and two out of four breast carcinomas available showed a loss of the BRCA1 wild-type allele, which in three out of four ovarian carcinomas analyzed by FISH was associated with duplication of the chromosome 17 containing the variant. Although the pathogenicity of the allele is strongly supported by the multifactorial ratio,we cannot exclude that p.His1673del is not itself deleterious, but is linked to another undetected mutation on the same ancestral allele.

Original languageEnglish
Pages (from-to)22640-22648
Number of pages9
Issue number14
Publication statusPublished - Jan 1 2017


  • BRCA1
  • Breast cancer
  • Hereditary cancer
  • Ovarian cancer
  • VUS

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype'. Together they form a unique fingerprint.

Cite this